Your browser doesn't support javascript.
loading
MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility.
Koenigsberg, Andrea L; Fowler, Veronica; Domike, Reuben; Brussel, Audrey; Barone, Paul W; Keumurian, Flora J; Leung, James; Wiebe, Michael E; Brewer, Michael T; Chan, Shawn; Dumey, Nicolas; Fournillier, Anne; Goodnight, Marcella; Kindermann, Johanna; Leavy, Richard; Lee, Buyoung; Minning, Stefan; Murphy, Marie; Myers, Eric; Nahabedian, Armen; Nanda, Kavita; Parriott, Sandi; Raju, G K; Scallan, Ciaran; Schoch, Stephanie; Shiminsky, Joe; Shum, Bonnie; Teitz, Sebastian; Westrek, Bernice; Springs, Stacy L.
Affiliation
  • Koenigsberg AL; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.
  • Fowler V; Oxford Nanopore Technologies, Oxford, United Kingdom.
  • Domike R; Light Pharma, Cambridge, MA.
  • Brussel A; Manufacturing Engineering at Brigham Young University, Provo, UT.
  • Barone PW; PathoQuest, Paris, France.
  • Keumurian FJ; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.
  • Leung J; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.
  • Wiebe ME; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.
  • Brewer MT; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.
  • Chan S; ThermoFisher, Waltham, MA.
  • Dumey N; Gritstone, Emeryville, CA.
  • Fournillier A; Sanofi, Marcy L'Étoile, France.
  • Goodnight M; Sanofi, Marcy L'Étoile, France.
  • Kindermann J; AstraZeneca, Gaithersburg, MD.
  • Leavy R; Takeda, Vienna, Austria.
  • Lee B; Amgen, Thousand Oaks, CA.
  • Minning S; Genentech, South San Francisco, CA.
  • Murphy M; Boehringer Ingelheim, Biberach, Germany.
  • Myers E; Eli Lilly, Dublin, Ireland.
  • Nahabedian A; Pfizer, Andover, MA.
  • Nanda K; Pfizer, Andover, MA.
  • Parriott S; Biogen, Durham, NC.
  • Raju GK; BioMarin, San Rafael, CA.
  • Scallan C; Light Pharma, Cambridge, MA.
  • Schoch S; Gritstone, Emeryville, CA.
  • Shiminsky J; CSL Behring, Marburg, Germany.
  • Shum B; BMS, Devens, MA.
  • Teitz S; Genentech, South San Francisco, CA.
  • Westrek B; Asahi Kasei, Cologne, Germany; and.
  • Springs SL; Merck & Co. Inc., Kenilworth, NJ.
PDA J Pharm Sci Technol ; 77(2): 115-132, 2023.
Article in En | MEDLINE | ID: mdl-36241212
ABSTRACT
Some members of MIT's Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) previously published content on the "Quality Risk Management in the Context of Viral Contamination", which described tools, procedures, and methodologies for assessing and managing the risk of a potential virus contamination in cell culture processes. To address the growing industry interest in moving manufacturing toward open ballrooms with functionally closed systems and to demonstrate how the ideas of risk management can be leveraged to perform a risk assessment, CAACB conducted a case study exercise of these new manufacturing modalities. In the case study exercise, a cross-functional team composed of personnel from many of CAACB's industry membership collaboratively assessed the risks of viral cross-contamination between a human and non-human host cell system in an open manufacturing facility. This open manufacturing facility had no walls to provide architectural separation of two processes occurring simultaneously, specifically a recombinant protein perfusion cell culture process using the human cell line, HEK-293 (Process 1) and a downstream postviral filtration unit operation (Process 2) of a recombinant protein produced in CHO cells. This viral risk assessment focused on cross-contamination of the Process 2 filtration unit operation after the Process 1 perfusion bioreactor was contaminated with a virus that went undetected. The workflow for quality risk management that is recommended by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was followed, which included identifying and mapping the manufacturing process, defining the risk question, risk evaluation, and risk control. The case study includes a completed Failure Mode and Effects Analysis (FMEA) to provide descriptions of the specific risks and corresponding recommended risk reduction actions.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Risk Management / Viruses Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: PDA J Pharm Sci Technol Journal subject: FARMACIA / FARMACOLOGIA Year: 2023 Document type: Article Affiliation country: Morocco

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Risk Management / Viruses Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: PDA J Pharm Sci Technol Journal subject: FARMACIA / FARMACOLOGIA Year: 2023 Document type: Article Affiliation country: Morocco